Group items tagged

To that end, the foundation is inviting applications for innovative research with the potential to increase the basic understanding of these uncommon tumors and lead to the development of more effective therapies. Grants ranging between $100,000 to $1.2 million will be awarded in support of projects over one to four years in the areas of basic, translational, or clinical neuroendocrine cancer research. Four different grants will be awarded: Accelerator Award - Grants of up to $1.2 million over four years will be awarded to projects that bring together investigators from diverse scientific disciplines. Investigator Awards - Grants of up to $300,000 over two years will be awarded to investigators and teams with the tools to study neuroendocrine cancers in innovative and transformative ways. Pilot Awards - Grants of up to $100,000 over one year will be awarded for pilot studies. Mentored Awards - Grants of up to $120,000 over two years will be awarded to encourage early-career investigators to pursue neuroendocrine tumor research and make a commitment to the field.

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.

The PFD Research Foundation together with the June Allyson Foundation has awarded over $1.5 million in grants to AUGS members since 1998. The Foundation serves the medical profession by supporting promising, innovative research regarding the causes, prevention, cure and treatment of pelvic floor disorders. Foundation research funds are made available to qualified AUGS members to pursue their research question. Goals of this research grant program are to support the completion of research projects which will lead to publication and presentation at future AUGS Annual Scientific Meetings and to support the development of researchers in the field who will go on to obtain additional funding for future research on pelvic floor disorders. Applicants can submit proposals for the following research awards: PFD Research Foundation Fellow Research Award: A two-year grant awarded to a fellow for clinical/patient-oriented, educational, or lab-based/basic science research. PFD Research Foundation Faculty Research Award: A two-year grant awarded to a junior faculty or affiliate member for clinical/patient-oriented, educational, or lab-based/basic science research. June Allyson Memorial Fund Research Award: A two-year grant awarded to a fellow for lab-based/basic science research. PFD Research Foundation and ICA IC/PBS Research Grant: A one-year grant awarded to a fellow, junior faculty or affiliate member of AUGS and ICA for research related to interstitial cystitis.

The Melanoma Research Foundation is accepting applications from emerging and established scientific investigators for research projects that explore new avenues in melanoma biology, prevention and treatments, with the goal of finding a cure. The foundation makes grants in four areas: Career Development Awards, Established Investigator Awards, Career Investigator CURE OM Awards, and Established Investigator CURE OM Awards. Career Development Awards provide funding of up to $50,000 a year for two years to junior investigators who are beginning a research career emphasizing melanoma-related projects and have not yet secured strong federal funding for their research. Established Investigator Awards provide funding of up to $100,000 a year for two years to established melanoma researchers or senior researchers working in closely related fields who wish to move into melanoma research. Career Development CURE OM Awards provide funding of up to $50,000 a year for two years to junior investigators in the ocular/uveal melanoma field. Established Investigator CURE OM Awards provides funding of up to $100,000 a year for two years to established ocular/uveal melanoma researchers, or senior researchers.

To that end, the two organizations have issued a Request for Applications for projects that test feasibility and generate preliminary data. MRA and ACS have each committed $1 million for the awards. The combined $2 million will be used to fund Multidisciplinary Team Awards and Pilot Awards. 1) Multidisciplinary Team Awards: At least one grant of up to $1 million will be awarded in this category are designed to foster interdisciplinary collaborative research to promote transformational advances with the potential for rapid clinical benefit. Letters of Intent must be received no later than August. Upon review, selected applicants will be invited to submit full applications by October 31, 2017. 2) Pilot Awards: Up to five grants of up to $200,000 each will be awarded over two years to help seed the ground in this relatively young area of checkpoint irAE research. Applications must be received no later than October 16, 2017.

The Melanoma Research Alliance (MRA) is pleased to announce the Second Release of its Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, staging, and treatment.  The 2020 - 2021 award cycle, is anticipated to support at least $7.6 million in new funding. Proposals will be accepted for Established Investigator, Academic-Industry Partnership, Young Investigator, and Pilot Awards.  This Second Release includes two new Special Opportunity awards focused on Melanoma Brain Metastasis, in partnership with the Rising Tide Foundation for Clinical Cancer Research. Other Special Opportunities include: Pediatric Melanoma Young Investigator Award with St. Baldrick's Foundation, UK or Israel-Based Young Investigator Award with Rosetrees Trust, Radiation Oncology Young Investigator Award with ASTRO (U.S. applicants only), and Immunotherapy Young Investigator Awards supported by Bristol Myers Squibb (BMS).

A. Noam Chomsky Global Connections Awards celebrate the power of human connections. The awards recognize distinguished service to the global mission of the STAR Scholars Network. Several individuals with a deep impact on advancing global, social mobility are recognized every year. We live in a time when innovation and creativity in support of humanity are of great importance. The Star Scholars Network recognizes the commitment of concerned people able and willing to make a difference in the lives of others. Nominations for this award are solicited from around the world. The nominee can be from any field. Beginning in 2020, the Star Scholars Network is committed to promoting transnational research, or collaborative research between scholars of two or more countries (e.g., joint publications, research partnerships, etc.). The Global Connections Awards recognize STAR Scholars for their achievements and distinctive contributions to translational research that demonstrates the very best of scholarly collaboration among scholars around the world. In December 2020, the Star Scholars Network will provide awards in three categories: North Star Medal of Lifetime Achievement, Shining Star Achievement in Research Award, Rising Star Emerging Scholar Certificate

Roche is pleased to announce that we are accepting applications for the 2013 TCRC Young Investigators Award.  The awards are intended to provide support for the earlier stages of scientific research career development, so they are to be awarded to the employing institutions of promising emerging researchers.  Proposals will be evaluated based on scientific merit and innovation of the projects proposed to be conducted using the awards.   Four awards will be presented on Oct 1, 2013 during the scientific symposium inaugurating Roche's Translational and Clinical Research Center in New York City.   Researchers performing investigations (clinical, in vitro/in vivo or informatics) focused on disease understanding of the following disease areas are encouraged to apply: Cardiovascular & Metabolism - Diabetes and related complications   Neuroscience - Spinal Muscular Atrophy Virology - Influenza Oncology - Treatment and diagnosis of Acute Myeloid Leukemia (AML).

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.

The Lila and Murray Gruber Memorial Cancer Research Award is one of the largest and most prestigious medical awards. The cash award of $10,000 will be made in recognition of the investigator's lifetime achievements in the field of cancer research. The award has been made possible by a gift from Murray Gruber in memory of his wife. Its purpose is to encourage participation in cancer research and to provide a forum for the enrichment of knowledge of dermatologists in this important scientific field. At the discretion of the task force, the award may be divided between two worthy nominees.

The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer. Since the intent of the Innovator Award mechanism is to recognize these remarkably creative and innovative, visionary individuals rather than projects, the central feature of the award is the innovative contribution that the Principal Investigator (PI) can make toward ending breast cancer. The PI should have a past record of challenging the status quo, shifting paradigms by changing a field of research or approach to patient care, exhibiting high levels of creativity, and demonstrating promise for continued innovation in future work. These rare individuals will be able to articulate a vision for ending breast cancer that challenges current dogma and demonstrates an ability to look beyond tradition and convention. The PI is also expected to be established in his/her field and have demonstrated success at forming and leading effective partnerships and collaborations. To further the development of innovative individuals and spark the generation of novel ideas, applications are required to incorporate the mentoring of promising junior investigators. Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research. This professional effort in breast cancer research can be through a combination of this award and other current support. Individuals from other disciplines who will apply novel concepts to breast cancer are encouraged to submit. The PI is expected to assemble a research team that will provide the n

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement/Funding Opportunity. An additional funding level, Funding Level 3, is available under a different Program Announcement (W81XWH-15-BCRP-BREAKTHROUGH2_FL3). It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: * Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required. * Funding Level 2: Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation. Demonstration of efficacy in in vivo models, as applicable. Partnering PI Option: The Breakthrough Award encourages applications that includ

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee. Applications will be evaluated based on the following:  - The applicant's capacity to conduct bold, exceptionally creative research. - The novelty and creativity of the proposed research. Incremental research will not be funded. - The potential of the proposed research to lead to advances that will significantly impact the prevention, diagnosis, treatment or basic understanding of cancer. - The applicant's lack of resources to pursue the proposed research.

The FY20 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research. A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations Also listed under: -Translational Research Partnership Award -Early-Career Investigator Award

The PRCRP Idea Award with Special Focus mechanism is intended to support innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are directly relevant to service members, their families, and other military beneficiaries. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The Idea Award with Special Focus is not intended to support a logical progression of an already established research project. The proposed research project should be novel and innovative. Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Research that is an incremental advance upon published data is not considered innovative and will not be considered for funding under this award mechanism. Inclusion of preliminary data is discouraged. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects to understand the mechanisms of initiation, or progression of cancer. This award is not intended to support ongoing research in the applicant's laboratory; therefore, inclusion of preliminary data other than serendipitous findings or in very small numbers is not consistent with the exploratory nature of this award.

The Childhood Brain Tumor Foundation (CBTF) is soliciting grant applications for the calendar year 2013. There will be two categories of awards: Pediatric Brain Tumor Grant Awards Our standard grant request for pediatric brain tumor awards will continue as usual. We anticipate funding up to three (3) research proposals that are a maximum of two years in duration. Funding requests cannot exceed $30,000/year or a maximum of $60,000 over the course of the award. Pilocytic Astrocytoma Award We have specific funds for one, 1-year research proposal related to pilocytic astrocytoma. The funding request for this award can be up to a maximum of $50,000.

The AACR and its Chemistry in Cancer Research Working Group established this award in 2007 to recognize the importance of chemistry to advancements in cancer research. The award will be given for outstanding, novel and significant chemistry research, which has led to important contributions to the fields of basic cancer research, translational cancer research, cancer diagnosis, the prevention of cancer or the treatment of patients with cancer. Such research may include, but is not limited to, drug discovery and design; structural biology; proteomics, metabolomics and biological mass spectrometry; chemical aspects of carcinogenesis; imaging agents and radiotherapeutics; and chemical biology. The winner of the Eighth Annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research will give a 50-minute lecture during the AACR Annual Meeting 2014 in San Diego, CA, USA (April 5-9, 2014), receive a commemorative award, a $10,000 honorarium, and receive support for the winner and a spouse to attend the Annual Meeting.

The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the "best and brightest" in their field(s) through extraordinary creativity, vision, leadership, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and should exhibit strong potential for future leadership in the breast cancer research community. As the intent of the Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the central features of the award are the applicant's demonstrated ability to go beyond conventional thinking in their field and the innovative contribution that the Principal Investigator (PI) can make toward ending breast cancer. The PI should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention. Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research. This professional effort in breast cancer research can be through a combination of this award and other current support. Individuals from other disciplines who will apply novel concepts to breast cancer are encouraged to submit. The PI is expected to assemble a research team that will provide the necessary expertise and collaborative efforts toward accomplishing the research goals. The PI's research team must include two or more breast cancer consumer advocates. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization.

The FY19 PRCRP Impact Award supports hypothesis-driven, high-impact research. The Impact Award mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical cancer issues, which, if successfully addressed, have the potential to make a major impact on at least one of the FY19 PRCRP Topic Areas. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples and trials. Through the Impact Award, the PRCRP seeks to build foundations for finding cures in under-funded, under-studied, and/or lethal militarily relevant cancer or research areas. With the Impact Award, PRCRP offers the unique opportunity to find commonalities in research across multiple cancers that advance the broader cancer field and to address cancer funding disparities within the FY19 PRCRP Topic Areas. The Impact Award supports identifying scientific outcomes through rigorous, robust research that are translatable toward treatment and/or preventive strategies. Research proposed should aim to accelerate promising findings toward clinical applicability and leverage research results to maximize impact.

The FY17 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research. The anticipated direct costs budgeted for the entire period of performance for an FY17 KCRP Concept Award will not exceed $75,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.